Felbamate in Intractable Childhood Epilepsy
نویسندگان
چکیده
منابع مشابه
Clinical Experience with Felbamate in Patients with Medically Intractable Epilepsy
RATIONALE: Felbamate (FBM) use has declined since 1994 following reports of FBM induced aplastic anemia and liver failure. Limited published data is available on the clinical experience of FBM use since 1994. We previously presented a preliminary report on a limited sample of adult patients treated at Minnesota Epilepsy Group. The current study significantly expands our observations on Felbamat...
متن کاملTopiramate for intractable childhood epilepsy
To better define the efficacy and tolerability of the new anticonvulsant topiramate in pediatric patients, the clinical courses of 49 children with intractable seizures were monitored during topiramate therapy. The 80% of children who had complex partial seizures experienced better seizure control with topiramate than the 20% who had generalized seizures. Efficacy was greatest with doses betwee...
متن کاملPredictors of intractable childhood epilepsy.
OBJECTIVE To determine the prognosis of seizures in epileptic children and identify early predictors of intractable childhood epilepsy. STUDY DESIGN Case-control study. PLACE AND DURATION OF STUDY The Epilepsy Centre of the Children's Hospital Lahore, from February 2005 to April 2007. PATIENTS AND METHODS All children (aged 1 month to 16 years) with idiopathic or cryptogenic epilepsy who ...
متن کاملmodified atkins diet for intractable childhood epilepsy
objective the aim of the present study was to evaluate the efficacy and tolerability of a modified atkins diet for intractable childhood epilepsy. materials & methods twenty one children with medically intractable epilepsy were enrolled in the study. inclusion criteria were at least four seizures per month and a trial of at least three anticonvulsants without becoming seizure-free. the subjects...
متن کاملThe use of felbamate in the treatment of patients with intractable epilepsy.
Background/justification. Epilepsy is a common condition, affecting up to 1% of the population. Until recently, there were only a handful of effective medications to treat this condition, many of which produced unwanted side effects or were capable of producing serious adverse events in some people. Despite these drawbacks, from 1978, when valproate was introduced, until 1993, no new therapies ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Neurology Briefs
سال: 1994
ISSN: 2166-6482,1043-3155
DOI: 10.15844/pedneurbriefs-8-5-5